BACKGROUND: Inflammation, oxidative damage, and platelet activation are hypothesized biological mechanisms driving the disablement process. The aim of the present study is to assess whether biomarkers representing these mechanisms predicted major adverse health-related events in older persons. METHODS: Data are from 2,234 community-dwelling nondisabled older persons enrolled in the Health Aging and Body Composition study. Biomarkers of lipid peroxidation (ie, urinary levels of 8-iso-prostaglandin F(2α)), platelet activation (ie, urinary levels of 11-dehydro-thromboxane B(2)), and inflammation (serum concentrations of interleukin-6) were considered as independent variables of interest and tested in Cox proportional hazard models as predictors of (severe) mobility disability and overall mortality. RESULTS: The sample's (women 48.0%, whites 64.3%) mean age was 74.6 (SD 2.9) years. During the follow-up (median 11.4 years), 792 (35.5%), 269 (12.0%), and 942 (42.2%) events of mobility disability, severe mobility disability, and mortality occurred, respectively. Only interleukin-6 showed significant independent associations with the onset of all the study outcomes. Higher levels of urinary 8-iso-prostaglandin F(2α) and 11-dehydro-thromboxane B(2) independently predicted increased risk of death (hazard ratio 1.10, 95% confidence interval 1.03-1.19 and hazard ratio 1.14, 95% confidence interval 1.06-1.23, respectively). No significant interactions of gender, race, cardiovascular disease, diabetes, and antiplatelet drugs were detected on the studied relationships. CONCLUSIONS: The inflammatory marker interleukin-6 is confirmed to be a robust predictor for the onset of negative health-related events. Participants with higher urinary levels of 8-iso-prostaglandin F(2α) and 11-dehydro-thromboxane B(2) presented a higher mortality risk.
BACKGROUND:Inflammation, oxidative damage, and platelet activation are hypothesized biological mechanisms driving the disablement process. The aim of the present study is to assess whether biomarkers representing these mechanisms predicted major adverse health-related events in older persons. METHODS: Data are from 2,234 community-dwelling nondisabled older persons enrolled in the Health Aging and Body Composition study. Biomarkers of lipid peroxidation (ie, urinary levels of 8-iso-prostaglandin F(2α)), platelet activation (ie, urinary levels of 11-dehydro-thromboxane B(2)), and inflammation (serum concentrations of interleukin-6) were considered as independent variables of interest and tested in Cox proportional hazard models as predictors of (severe) mobility disability and overall mortality. RESULTS: The sample's (women 48.0%, whites 64.3%) mean age was 74.6 (SD 2.9) years. During the follow-up (median 11.4 years), 792 (35.5%), 269 (12.0%), and 942 (42.2%) events of mobility disability, severe mobility disability, and mortality occurred, respectively. Only interleukin-6 showed significant independent associations with the onset of all the study outcomes. Higher levels of urinary 8-iso-prostaglandin F(2α) and 11-dehydro-thromboxane B(2) independently predicted increased risk of death (hazard ratio 1.10, 95% confidence interval 1.03-1.19 and hazard ratio 1.14, 95% confidence interval 1.06-1.23, respectively). No significant interactions of gender, race, cardiovascular disease, diabetes, and antiplatelet drugs were detected on the studied relationships. CONCLUSIONS: The inflammatory marker interleukin-6 is confirmed to be a robust predictor for the onset of negative health-related events. Participants with higher urinary levels of 8-iso-prostaglandin F(2α) and 11-dehydro-thromboxane B(2) presented a higher mortality risk.
Authors: L P Fried; N O Borhani; P Enright; C D Furberg; J M Gardin; R A Kronmal; L H Kuller; T A Manolio; M B Mittelmark; A Newman Journal: Ann Epidemiol Date: 1991-02 Impact factor: 3.797
Authors: B E Ainsworth; W L Haskell; A S Leon; D R Jacobs; H J Montoye; J F Sallis; R S Paffenbarger Journal: Med Sci Sports Exerc Date: 1993-01 Impact factor: 5.411
Authors: Z Wang; G Ciabattoni; C Créminon; J Lawson; G A Fitzgerald; C Patrono; J Maclouf Journal: J Pharmacol Exp Ther Date: 1995-10 Impact factor: 4.030
Authors: Zoltan Ungvari; Zsuzsanna Tucsek; Danuta Sosnowska; Peter Toth; Tripti Gautam; Andrej Podlutsky; Agnes Csiszar; Gyorgy Losonczy; M Noa Valcarcel-Ares; William E Sonntag; Anna Csiszar Journal: J Gerontol A Biol Sci Med Sci Date: 2012-12-13 Impact factor: 6.053
Authors: Nam V Vo; Robert A Hartman; Prashanti R Patil; Makarand V Risbud; Dimitris Kletsas; James C Iatridis; Judith A Hoyland; Christine L Le Maitre; Gwendolyn A Sowa; James D Kang Journal: J Orthop Res Date: 2016-08-12 Impact factor: 3.494
Authors: Anna Csiszar; Danuta Sosnowska; Zsuzsanna Tucsek; Tripti Gautam; Peter Toth; Gyorgy Losonczy; Ricki J Colman; Richard Weindruch; Rozalyn M Anderson; William E Sonntag; Zoltan Ungvari Journal: J Gerontol A Biol Sci Med Sci Date: 2012-08-17 Impact factor: 6.053
Authors: M Kyla Shea; Richard F Loeser; Fang-Chi Hsu; Sarah L Booth; Michael Nevitt; Eleanor M Simonsick; Elsa S Strotmeyer; Cees Vermeer; Stephen B Kritchevsky Journal: J Gerontol A Biol Sci Med Sci Date: 2015-11-17 Impact factor: 6.053
Authors: Gregory J Tranah; Kristine Yaffe; Shana M Katzman; Ernest T Lam; Ludmila Pawlikowska; Pui-Yan Kwok; Nicholas J Schork; Todd M Manini; Stephen Kritchevsky; Fridtjof Thomas; Anne B Newman; Tamara B Harris; Anne L Coleman; Michael B Gorin; Elizabeth P Helzner; Michael C Rowbotham; Warren S Browner; Steven R Cummings Journal: J Gerontol A Biol Sci Med Sci Date: 2015-08-31 Impact factor: 6.053
Authors: Gregory J Tranah; Jennifer S Yokoyama; Shana M Katzman; Michael A Nalls; Anne B Newman; Tamara B Harris; Matteo Cesari; Todd M Manini; Nicholas J Schork; Steven R Cummings; Yongmei Liu; Kristine Yaffe Journal: Neurobiol Aging Date: 2013-10-18 Impact factor: 4.673